Characteristics of G-CSF therapy by ELA2 genotype
. | SCN group . | . | . | CN group . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|---|
. | NN . | NM . | P . | NN . | NM . | P . | ||||
No. patients | 35 | 19 | — | 15 | 12 | — | ||||
Prevalence of patients undergoing G-CSF therapy, n (%) | 15 (43) | 18 (95) | .0001 | 6 (40) | 9 (75) | NS | ||||
Median G-CSF dose per injection, μg/kg (minimum-maximum) | 9.2 (2-32) | 9.9 (2.8-36) | NS | 4.2 (1.6-5) | 5.1 (2-9.9) | NS | ||||
Frequency of G-CSF injections* | 2.1 | 5.3 | .007 | 5 | 2.5 | NS |
. | SCN group . | . | . | CN group . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|---|
. | NN . | NM . | P . | NN . | NM . | P . | ||||
No. patients | 35 | 19 | — | 15 | 12 | — | ||||
Prevalence of patients undergoing G-CSF therapy, n (%) | 15 (43) | 18 (95) | .0001 | 6 (40) | 9 (75) | NS | ||||
Median G-CSF dose per injection, μg/kg (minimum-maximum) | 9.2 (2-32) | 9.9 (2.8-36) | NS | 4.2 (1.6-5) | 5.1 (2-9.9) | NS | ||||
Frequency of G-CSF injections* | 2.1 | 5.3 | .007 | 5 | 2.5 | NS |
NS indicates not significant; NN genotype, patient with no ELA2 mutation; NM genotype, patient with a heterozygous ELA2 mutation; and —, not applicable.
Frequency of G-CSF injections is given for a 10-day period